You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

fluzoparib

Showing 1 - 25 of 32
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer Trial in Guangzhou (Fluzoparib, Fluzoparib+Camrelizumab)

Recruiting
  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
  • Guangzhou, Guangdong, China
    Sun-yat sen university cancer center
Jan 27, 2023

Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors Trial in Guangzhou (Fluzoparib, Radioactive particle

Recruiting
  • Sarcoma,Soft Tissue
  • +2 more
  • Fluzoparib
  • Radioactive particle implantation
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • Fluzoparib
  • +7 more
  • (no location specified)
Jun 5, 2023

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

Not yet recruiting
  • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery Fudan University Shanghai Caner
Feb 22, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Fluzoparib
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 23, 2022

High-risk Prostate Cancer, Neoadjuvant Therapy Trial in Shanghai (Abiraterone acetate, Fluzoparib, Prednisone)

Recruiting
  • High-risk Prostate Cancer
  • Neoadjuvant Therapy
  • Abiraterone acetate
  • +4 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 6, 2022

Soft Tissue Sarcoma Trial in Beijing (Fluzoparib, Preoperative moderately fractionated radiotherapay)

Recruiting
  • Soft Tissue Sarcoma
  • Fluzoparib
  • Preoperative moderately fractionated radiotherapay
  • Beijing, Beijing, China
  • +1 more
Jul 3, 2023

Ovarian Cancer Trial (Fluzoparib, QL1101)

Not yet recruiting
  • Ovarian Cancer
  • Fluzoparib
  • QL1101
  • (no location specified)
Oct 18, 2022

Advanced Solid Tumor Trial in Changsha (Fluzoparib, Omeprazole)

Completed
  • Advanced Solid Tumor
  • Changsha, Hunan, China
    The third xiangya hospital Hospital,of central south university
Jul 28, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Beijing (Fluzoparib; Apatinib, Fluzoparib, Placebo)

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Fluzoparib; Apatinib
  • +2 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 22, 2022

Renal Cell Carcinoma Trial in Nanjing (Fluzoparib)

Recruiting
  • Renal Cell Carcinoma
  • Fluzoparib
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Feb 19, 2022

Ovarian Cancer Trial in Tai'an (Bevacizumab, chemo, Fluzoparib)

Recruiting
  • Ovarian Cancer
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
Dec 24, 2021

Relapsed Ovarian Cancer Trial in Hangzhou (Fluzoparib+Apatinib, Fluzoparib)

Recruiting
  • Relapsed Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 25, 2021

Renal Impairment Trial (Fluzoparib)

Not yet recruiting
  • Renal Impairment
  • Fluzoparib
  • (no location specified)
Aug 27, 2021

Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Fluzoparib
  • +2 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

NSCLC Trial in Tianjin (biological, drug, radiation)

Recruiting
  • Non-small Cell Lung Cancer
  • Camrelizumab
  • +5 more
  • Tianjin, China
    Liu ningbo
May 7, 2021

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Hepatic Impairment, Healthy Subjects Trial in Zhengzhou (Fluzoparib)

Recruiting
  • Hepatic Impairment
  • Healthy Subjects
  • Fluzoparib
  • Zhengzhou, Henan, China
    Henan Infectious Diseases Hospital
Jan 3, 2021

Pancreatic Cancer Trial in Shanghai (Fluzoparib)

Recruiting
  • Pancreatic Cancer
  • Fluzoparib
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Dec 30, 2020

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Small Cell Lung Cancer Extensive Stage Trial in Tianjin (Fluzoparib, Apatinib)

Recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Dec 2, 2020

Healthy Adult Subjects Trial in Qingdao (Fluzoparib)

Completed
  • Healthy Adult Subjects
  • Fluzoparib
  • Qingdao, Qingdao, China
    The affiliated hospital of QingDao university
Aug 19, 2020

Advanced Pancreatic Cancer Trial in Shanghai, Hangzhou (Fluzoparib, Fluzoparib , mFOLFIRINOX)

Recruiting
  • Advanced Pancreatic Cancer
  • Fluzoparib
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Aug 9, 2020